Market Expansion, Strong Sales, Regulatory Filings, and FDA Approvals - Research Report on Thermo Fisher, BioMarin, The Medicines Company, Acura Pharmaceuticals, and Endologix

NEW YORK, July 4, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Thermo Fisher Scientific Inc. (NYSE: TMO), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), The Medicines Company (NASDAQ: MDCO), Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) and Endologix, Inc. (NASDAQ: ELGX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Thermo Fisher Scientific Inc. Research Report

On June 25, 2013, Thermo Fisher Scientific Inc. (Thermo Fisher) announced that it has established the China Innovation Center in Shanghai, with an aim to significantly expand its research, development and training capabilities to support high-growth markets in the Asia-Pacific region. The company reportedly invested $9.5 million in the Shanghai Center to support its rapidly growing R&D organization, which is expected to add 200 to 300 engineers during the next two to three years. Further, Thermo Fisher stated that the new facility will include a Technology Training Center to instruct up to 2,500 customers per year in the use of its industry-leading chromatography and mass spectrometry systems, among other technologies. Marc N. Casper, President and Chief Executive Officer of Thermo Fisher Scientific, said, "China is one of our fastest-growing markets and continues to be a key contributor to our success. The China Innovation Center builds on our well-established local presence and is an important next step as we align our product development efforts with investments in our manufacturing infrastructure." The Full Research Report on Thermo Fisher Scientific Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/45ea_TMO]

--

BioMarin Pharmaceutical Inc. Research Report

On July 1, 2013 BioMarin Pharmaceutical Inc. (BioMarin) announced the submission of Vimizim Marketing Application (MA) to the Agência Nacional de Vigilancia Sanitaria (ANVISA), or the National Health Surveillance Agency Brazil. Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin, said, "Considering that Brazil, along with the U.S., are expected to be the largest market opportunities for Vimizim, the timely submission in this market is an important milestone in our efforts to bring the first therapeutic option to patients with Morquio A Syndrome." Based on its orphan drug status in the U.S. and EU, as well as its priority review status, the Company expects an approval decision from ANVISA in mid-2014. The Full Research Report on BioMarin Pharmaceutical Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/936c_BMRN]

--

The Medicines Company Research Report

On July 1, 2013, The Medicines Company (The Medicines) announced that the US Food and Drug Administration (FDA) accepted the filing of the new drug application (NDA) for its investigational intravenous antiplatelet cangrelor. According to the Company, cangrelor is intended for use in patients undergoing percutaneous coronary intervention (PCI) and those that require bridging from oral antiplatelet therapy to surgery. The Medicines informed that the filing was based on the results of a comprehensive development program, that included data from four randomized, double-blind clinical trials conducted in over 25,000 patients with coronary artery disease (CHAMPION PHOENIX, CHAMPION PLATFORM, CHAMPION PCI, and BRIDGE). Simona Skerjanec, PharmD, MBA, Senior Vice President and Innovation Leader for Antiplatelet Therapies at The Medicines, said, "With filing of the NDA now complete, we will work closely with the FDA to advance the review process for cangrelor during the next 10 months. If the review is successful, we anticipate U.S. market approval in the second quarter of 2014. We remain on track for an anticipated European submission in the fourth quarter 2013." The Full Research Report on The Medicines Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/518a_MDCO]

--

Acura Pharmaceuticals, Inc. Research Report

On July 1, 2013, Acura Pharmaceuticals (Acura Pharma) announced that Pfizer will expand commercialization of OXECTA (oxycodone HCI) Tablets CII to health care providers in Q4 2013. According to the Company, commercialization activities will be directed to a national cross section of healthcare professionals who treat pain, but will not include the use of field representatives. Acura Pharma reported that it has exclusively licensed its AVERSION Technology to Pfizer in the United States, Canada, and Mexico for use in OXECTA and receives tiered royalties ranging from 5% to 25% on net sales (gross sales less discounts, if any) of OXECTA. The Full Research Report on Acura Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:  [http://www.wsreports.com/r/full_research_report/1f21_ACUR]

--

Endologix, Inc. Research Report

On July 1, 2013, Endologix Inc. (Endologix) announced preliminary unaudited revenue for Q2 2013. The Company expects its Q2 2013 global revenue to grow 33% YoY and 14% QoQ to approximately $34 million. Further, Endologix expects its US revenue to grow 23% YoY to $26.3 million, and international revenue to grow 81% YoY to $7.6 million. Commenting on its preliminary results, John McDermott, Endologix Chairman, President and Chief Executive Officer, said, "We achieved strong sales growth during the second quarter, as a result of the excellent outcomes achieved by physicians with the AFX Endovascular AAA System and the support provided by our sales and clinical people. Accordingly, we have raised our revenue guidance for the year and remain confident in our long-term outlook for sales growth of approximately 20% or greater year-over-year over the next several years." The Full Research Report on Endologix, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/2388_ELGX]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Wall Street Reports